ConvaTec Group (CTEC) Trading Update summary
Event summary combining transcript, slides, and related documents.
Trading Update summary
15 Jan, 2026Financial performance and guidance
Organic sales growth reached 7.7% for the first 10 months, with all four categories contributing and stronger growth in the second half.
Upgraded FY 2024 organic sales growth guidance to 7.25%-8% and constant currency margin guidance to at least 21.5%, driven by improved gross margin and lower inflation.
Double-digit growth in adjusted EPS and free cash flow to equity is expected for 2024 and 2025, irrespective of LCD outcomes, with further margin expansion in 2025.
Foreign exchange is expected to reduce reported FY24 operating margin by about 70bps; interest, tax, and capex guidance remain unchanged.
For 2025, excluding InnovaMatrix, 96% of group sales are expected to grow 5%-7%, with continued operating margin expansion.
Business segment highlights
Advanced Wound Care saw high single-digit growth, with InnovaMatrix sales up 40% year-to-date and no expected negative impact from draft LCDs in 2024.
Ostomy Care achieved mid-single-digit growth, led by emerging markets and strong uptake of Esteem Body in Europe and the U.S.
Continence Care delivered high single-digit growth, driven by product portfolio expansion and strong customer service, with GentleCath Air for Women performing well.
Infusion Care posted high single-digit growth, with strong demand in both diabetes and non-diabetes treatments and new product launches, including Neria Guard for Parkinson's.
Emerging markets, especially Brazil, Colombia, and China, are driving double-digit growth in Ostomy Care.
Product innovation and pipeline
New product pipeline is robust, with seven launches planned for 2025 and 2026.
ConvaFoam, Esteem Body, and GentleCath Air for Women have shown strong market uptake; Natura Body (two-piece version) is planned for 2026.
GentleCath Air for Women is seeing strong uptake and positive feedback, with the male version on track for 2026.
Infusion Care is expanding into non-diabetes applications, with AbbVie's Parkinson's product launch in the U.S. expected to boost growth.
AI is being explored to enhance productivity in customer service and translation.
Latest events from ConvaTec Group
- Strong 2025 growth, margin expansion, and upgraded 2027 targets with robust cash generation.CTEC
H2 202524 Feb 2026 - 6.6% organic revenue growth, margin expansion, and robust outlook with double-digit EPS targets.CTEC
H1 20242 Feb 2026 - Double-digit EPS and cash flow growth, margin expansion, and strong 2025 outlook despite headwinds.CTEC
H2 202416 Dec 2025 - Tightened FY25 guidance to 5.5%-7% growth, driven by innovation and broad-based category gains.CTEC
Trading Update21 Nov 2025 - H1 2025 saw strong growth, margin expansion, and double-digit EPS gains with guidance reaffirmed.CTEC
H1 202516 Nov 2025 - Strong growth, innovation, and margin expansion drive confidence despite InnovaMatrix headwinds.CTEC
Trading Update13 Nov 2025